BOSTON--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced it has raised an oversubscribed $5.2 million seed round led by The Engine Ventures. Additional participating investors include Illumina Ventures, Time Boost Capital, the American Cancer Society Bright Edge and the Oetgen family.

波士顿--（商业新闻短讯）--Predicta Biosciences是一家开发新型诊断和治疗产品的精准肿瘤学公司，今天宣布，它已经筹集到由Engine Ventures牵头的520万美元超额认购的种子轮。其他参与投资者包括Illumina Ventures、Time Boost Capital、美国癌症协会Bright Edge和Oetgen家族。

Jay Wohlgemuth, former CMO of Quest Diagnostics, Mara Aspinall, former CEO of Roche Tissue Diagnostics and Partner at Illumina VC, and Ann DeWitt, General Partner at The Engine Ventures, will join the company’s Board. Predicta will use the seed funding to expand its team, and build a CLIA lab and workflow for sequencing and bioinformatics..

Quest Diagnostics前首席执行官Jay Wohlgemuth、罗氏组织诊断前首席执行官兼Illumina VC合伙人Mara Aspinall和Engine Ventures普通合伙人Ann DeWitt将加入公司董事会。Predicta将利用种子基金扩大其团队，并为测序和生物信息学建立一个CLIA实验室和工作流程。。

Predicta was founded in 2023 at Blavatnik Harvard Life Lab Longwood by leading academics from Harvard Medical School and MIT and clinicians in the field of multiple myeloma and cancer genomics spanning Dana-Farber Cancer Institute and the Broad Institute. Company co-founders include Irene Ghobrial, MD, Kenneth C.

Predicta于2023年在Blavatnik哈佛生命实验室Longwood成立，由哈佛医学院和麻省理工学院的顶尖学者以及跨越Dana-Farber癌症研究所和Broad研究所的多发性骨髓瘤和癌症基因组学领域的临床医生创立。公司联合创始人包括医学博士艾琳·戈布里亚（IreneGhobrial）和肯尼斯·C。

Anderson, MD, Gad Getz, PhD, and Romanos Sklavenitis-Pistofidis, MD PhD. All are leaders in their respective disease indications and cancer clinical research, collectively identifying an unmet need for non-invasive diagnostics and pioneering experimental and computational biology and tools to better analyze cancer genomes..

医学博士安德森（Anderson），医学博士加德盖茨（Gad Getz）和医学博士罗曼诺斯·斯科拉文蒂斯·皮斯托菲迪斯（Romanos Sklavenitis Pistofidis）。他们都是各自疾病适应症和癌症临床研究的领导者，共同确定了对非侵入性诊断的未满足需求，以及开创性的实验和计算生物学以及更好地分析癌症基因组的工具。。

The advent of precision medicine has led to significant advances in therapeutics, however a large gap remains in diagnostics, which impacts the effectiveness of clinical trials and patient outcomes. For example, bone marrow biopsies and fluorescence in situ hybridization (FISH) tests are frequently used as blood cancer diagnostics, however they are 50+ year old tools, invasive, and have high failure rates and low sensitivity, making it difficult to diagnose and monitor patients.

精准医学的出现导致了治疗学的重大进步，但诊断学仍存在很大差距，这影响了临床试验的有效性和患者的预后。例如，骨髓活检和荧光原位杂交（FISH）测试经常被用作血癌诊断，但它们是50多年前的工具，具有侵入性，失败率高，灵敏度低，难以诊断和监测患者。

For blood cancers with no cure – including multiple myeloma, the second most common blood cancer after lymphoma with ~35,000 newly diagnosed patients every year in the U.S. – it’s particularly crucial to diagnose as early as possible and identify targeted therapies with lower toxicity, as this can extend a patient’s life and ensure a higher quality of life..

对于无法治愈的血癌-包括多发性骨髓瘤，这是美国仅次于淋巴瘤的第二大常见血癌，每年约有35000名新诊断患者-尽早诊断并确定毒性较低的靶向治疗尤为重要，因为这可以延长患者的寿命并确保更高的生活质量。。

Predicta is building a diagnostic and monitoring platform that provides targeted information for diagnosis, treatment decisions and patient monitoring, and replaces painful bone marrow biopsies with simple blood draws. The company’s non-invasive diagnostic tests initially focus on multiple myeloma, a disease that develops from two asymptomatic precursors that can be identified and treated proactively.

Predicta正在建立一个诊断和监测平台，为诊断、治疗决策和患者监测提供有针对性的信息，并用简单的抽血代替痛苦的骨髓活检。该公司的非侵入性诊断测试最初侧重于多发性骨髓瘤，这种疾病是由两种无症状的前体发展而来的，可以主动识别和治疗。

The company’s first product, GenoPredicta, provides more detailed and complete information on a patient’s multiple myeloma compared to existing market options, and offers sophisticated algorithmic analysis for risk stratification and treatment optimization. Currently, GenoPredicta is being used in a research capacity at Dana Farber, with plans to launch the diagnostic product commercially early next year..

该公司的第一款产品GenoPredicta与现有的市场选择相比，提供了有关患者多发性骨髓瘤的更详细和完整的信息，并为风险分层和治疗优化提供了复杂的算法分析。目前，GenoPredicta正在达纳·法伯（DanaFarber）进行研究，计划明年年初将该诊断产品投入商业运营。。

“Predicta is passionate about early cancer detection and transforming the patient experience. Our mission is twofold: to deliver non-invasive tests that diagnose cancer in the earliest stages, and develop a one-of-a-kind clinical database that identifies new drug targets and immune signatures,” said Kate Caves, CEO of Predicta.

Predicta首席执行官Kate Caves说：“Predicta热衷于早期癌症检测和改变患者体验。我们的使命有两个：提供非侵入性检测，在早期诊断癌症，并开发一种独一无二的临床数据库，用于识别新药靶点和免疫特征。”。

“For precision medicine to succeed, we need to empower physicians with the tools and knowledge required to make informed decisions and provide the best possible care. Predicta is using blood-based multi-omics to more easily diagnose patients sooner, and enable personalized monitoring and treatment throughout their care journey.”.

“为了使精准医学取得成功，我们需要赋予医生做出明智决策所需的工具和知识，并提供尽可能最好的护理。Predicta正在使用基于血液的多组学更快地诊断患者，并在整个护理过程中实现个性化监测和治疗。”。

In addition to its diagnostic and monitoring platform, Predicta is compiling extensive genomic and transcriptomic data from pre and post treatment timepoints, and using AI to mine the data for novel target discovery and therapeutics development. The company’s diagnostics and growing clinical database will benefit current and future blood cancer patients, their caregivers, physicians and insurers.

除了诊断和监测平台外，Predicta还从治疗前后的时间点汇编了大量的基因组和转录组数据，并使用AI挖掘数据，以发现新的靶标和开发治疗方法。该公司的诊断和不断增长的临床数据库将使当前和未来的血癌患者、其护理人员、医生和保险公司受益。

Predicta plans to eventually expand its diagnostic and monitoring platform into lymphoma and autoimmune conditions..

Predicta计划最终将其诊断和监测平台扩展到淋巴瘤和自身免疫性疾病。。

“The Predicta team cares deeply about empowering not only physicians, but also patients with detailed information about their unique molecular data, treatment options and monitoring recommendations,” said Kenneth Anderson, clinical co-founder of Predicta. “In addition to providing more complete information on a patient’s multiple myeloma, our tests evaluate patients’ immune system cells, equipping physicians with the unique and critical ability to determine the likelihood of a patient responding to new immunotherapies like CAR T-cell therapy and Bispecific antibodies.”.

Predicta的临床联合创始人肯尼斯·安德森（KennethAnderson）说：“Predicta团队不仅非常关心赋予医生权力，还关心患者有关其独特分子数据、治疗选择和监测建议的详细信息。”。“除了提供有关患者多发性骨髓瘤的更完整信息外，我们的测试还评估患者的免疫系统细胞，使医生具备独特而关键的能力来确定患者对CAR T细胞疗法和双特异性抗体等新免疫疗法作出反应的可能性。”。

Added DeWitt, “There’s a massive need for new therapeutic targets in blood cancers, as few cures exist and many existing treatments are highly toxic. Predicta is uniquely positioned to transform both the discovery and development of new therapeutics. The company stands to make a truly meaningful impact, not only because of its early partnerships and financing, but also because of its incredible team of academic and clinical experts who bring invaluable domain expertise.”.

德维特补充道：“由于治愈方法很少，许多现有的治疗方法毒性很高，因此对血癌的新治疗靶点需求巨大。Predicta在改变新疗法的发现和开发方面具有独特的地位。该公司将产生真正有意义的影响，不仅因为其早期的合作伙伴关系和融资，还因为其令人难以置信的学术和临床专家团队带来了宝贵的领域专业知识。”。

The company is led by CEO Kate Caves, CFO Joanne Bryce and SVP of Translational Research Aparna Raval, PhD. Caves brings more than a decade of senior corporate development experience from 10x Genomics, Abcam, Zymergen and Atum Bio. Bryce brings more than two decades of CFO experience at Disc Medicine, Dyne and other high profile biotechs.

该公司由首席执行官凯特·卡夫（KateColves）、首席财务官乔安妮·布莱斯（JoanneBryce）和转化研究高级副总裁阿帕纳·拉瓦尔（AparnaRaval）博士领导。Caves为10x Genomics、Abcam、Zymergen和Atum Bio带来了十多年的高级企业发展经验。Bryce为Disc Medicine、Dyne和其他备受瞩目的生物技术公司带来了二十多年的首席财务官经验。

Formerly an Executive Director at Bristol Myers Squibb and a Senior Scientist at Genentech, Raval brings more than two decades of experience in translational and clinical research of hematological malignancies..

Raval曾任百时美施贵宝（Bristol-Myers Squibb）执行董事和基因泰克（Genentech）高级科学家，在血液系统恶性肿瘤的转化和临床研究方面拥有20多年的经验。。

To drive early adoption and demonstrate clinical utility of its diagnostic and monitoring platform, Predicta is actively pursuing additional partnerships with academic medical centers and pharmaceutical companies. To learn more about the company or inquire about partnership opportunities, visit: https://www.predictabiosciences.com/.

为了推动早期采用并证明其诊断和监测平台的临床实用性，Predicta正在积极寻求与学术医疗中心和制药公司的额外合作伙伴关系。要了解有关公司的更多信息或询问合作机会，请访问：https://www.predictabiosciences.com/.

About Predicta Biosciences

关于Predicta Biosciences

Founded by leading cancer genomics researchers and clinicians, Predicta is a precision oncology company developing novel diagnostic and therapeutic products. The company’s non-invasive diagnostics initially focus on multiple myeloma and evaluate patients’ immune system cells, equipping physicians with the unique ability to determine the likelihood of a patient responding to immunotherapies.

Predicta由领先的癌症基因组学研究人员和临床医生创建，是一家开发新型诊断和治疗产品的精密肿瘤学公司。该公司的非侵入性诊断最初专注于多发性骨髓瘤，并评估患者的免疫系统细胞，使医生具备确定患者对免疫疗法有反应的可能性的独特能力。

Leveraging extensive genomic and transcriptomic patient data, Predicta is also building a one-of-a-kind clinical database for identifying new therapeutic targets. The company is supported by The Engine Ventures, Illumina Ventures, the American Cancer Society, Dana-Farber Cancer Institute and the former CMO of Quest Diagnostics, among others.

Predicta还利用广泛的基因组和转录组患者数据，建立了一个独一无二的临床数据库，用于确定新的治疗靶点。该公司得到了Engine Ventures、Illumina Ventures、美国癌症协会、Dana Farber癌症研究所和Quest Diagnostics的前CMO等机构的支持。

For more information, visit www.predictabiosciences.com or follow the company on LinkedIn..

有关更多信息，请访问www.predictabiosciences.com或在LinkedIn上关注该公司。。